Hualan Biological Bacterin Inc
SZSE:301207
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15.63
31.68
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hualan Biological Bacterin Inc
Change in Working Capital
Hualan Biological Bacterin Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
H
|
Hualan Biological Bacterin Inc
SZSE:301207
|
Change in Working Capital
-ÂĄ939.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Change in Working Capital
-ÂĄ12.8B
|
CAGR 3-Years
-278%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Change in Working Capital
ÂĄ490.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Change in Working Capital
-ÂĄ3.9B
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Change in Working Capital
-ÂĄ1.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-22%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Change in Working Capital
-ÂĄ3.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-32%
|
Hualan Biological Bacterin Inc
Glance View
Hualan Biological Bacterin Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. Hualan Biological Bacterin Inc is a China-based company specializing in the research, development, production and sales of human vaccines. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.
See Also
What is Hualan Biological Bacterin Inc's Change in Working Capital?
Change in Working Capital
-939.7m
CNY
Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Change in Working Capital amounts to -939.7m CNY.
What is Hualan Biological Bacterin Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-30%
Over the last year, the Change in Working Capital growth was -36%. The average annual Change in Working Capital growth rates for Hualan Biological Bacterin Inc have been -20% over the past three years , -30% over the past five years .